2022 Annual General Meeting of Shareholders
Release time:
2023-06-07
The on-site meeting of the shareholders' meeting was convened by the board of directors of the company and presided over by Chairman Jiang Xiaomeng. Company directors, supervisors and the secretary of the board of directors to attend the meeting, all senior management personnel to attend the meeting. The meeting was held and voted by a combination of on-site voting and online voting. A total of 109 shareholders and proxies attended the meeting, and the total number of voting shares held was 71,270,170, accounting for 20.7130 of the company's total voting shares. The meeting reviewed and approved the 2022 board of directors report, the 2022 board of supervisors report, the 2022 financial final accounts report, the 2022 profit distribution plan, the proposal on hiring the company's 2023 audit agency, the proposal on providing guarantees for holding subsidiaries, the 2022 annual report and Seven proposals including its summary. The meeting also heard the 2022 annual debriefing report of independent directors. According to the annual report of the board of directors of
, in 2023, the company will focus on the working policy of "reform, innovation and strong advantages; cost reduction, quality improvement and efficiency increase", continuously extend and develop the two main businesses of building materials and medicine, cultivate health products, logistics and other businesses, and further improve the relatively diversified business framework with complementary cycles. The building materials business sector, with cement manufacturing as the core, continues to extend to the upstream and downstream industrial chain, creates comprehensive advantages, and cultivates new growth points; increases the use of alternative energy and green energy; at the same time, continue to strive for the layout of new cement projects in areas with markets and resources; relying on management and technical advantages, continue to find suitable target projects. The pharmaceutical business sector, with products as the core, accelerates the formation of a complete business chain from raw materials to preparations, builds cost and quality advantages, and enhances product competitiveness; guided by clinical value, increases investment in research and development, creates varieties and technical advantages, and promotes enterprise development. In other sectors, the company's health products business is mainly health products, which will jointly drive the extraction of Chinese herbal pieces and plants to further create a development pattern of "one main body with two wings". Taking advantage of the location advantage of the peak supply chain, large e-commerce logistics companies will be introduced, spot storage business will be vigorously developed, futures delivery varieties will be gradually increased, and a platform for storage and distribution of bulk commodities will be built. (remaining fruit)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page